Page 98 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation

Chapter 4
Supplemental Table 3. Interobserver agreement of specific nodal and extranodal localizations in EoT-PET.
Number baseline positive
Number of discrepancies at EoT-PET
Agreement on negativity (absolute)
Agreement on positivity (absolute)
Percentage overall agreement‡
Related to baseline prevalence§
Nodal
Para-aortic† 397 17 Cervical† 286 6 Iliac† 267 8 Axillary† 220 1 Supraclavicular† 213 2 Inguinal† 204 5 Mediastinal* 202 5 Mesenteric 188 17 Hilar*† 142 8 Spleen* 114 6 Other 105 6 Waldeyer 48 1 Extranodal
Other 123 13 extranodal*
Skeletal* 90 8 GI* 62 6 Lung* 54 3 Liver* 38 2 Pleura* 25 0 Skin 13 1 CNS 0 0
884 13 903 5 899 7 909 4 908 4 908 1 442 8 429 11 897 1 442 8 450 1 456 0
431 10
441 5 444 6 445 6 453 1 456 0 456 0 456 1
98.1 4.3% 99.3 2.1% 99.1 3.0% 99.9 0.5% 99.8 0.9% 99.5 2.5% 98.9 2.5% 96.3 9.0% 99.1 5.6% 98.7 5.4% 98.7 5.7% 99.8 2.1%
97.1 10.6%
98.2 8.9% 98.7 9.7% 99.3 5.6% 99.6 5.3% 100.0 0.0% 99.8 7.7% 100.0 0.0%
Abbreviations: CNS= central nervous system; EoT-PET= end-of-treatment positron emission tomography; GI= gastrointestinal
* Totals not 457 or 914, because of missing values or localization scored as unclear.
† Right and left are summed and presented together.
‡Percentage overall agreement: (number of agreement on positivity + number of agreement on negativity) / (number of discrepancies + number of agreement on positivity + number of agreement on negativity)*100%. §Related to baseline prevalence: (number of discrepancies/number baseline positive)*100%.
96